For a male patient receiving testosterone replacement therapy who has a serum testosterone of 174 ng/dL, should the dose be increased?

Yes, Increase the Dose

A testosterone level of 174 ng/dL is well below the target mid-normal range (450-600 ng/dL), and the dose should be increased to achieve therapeutic testosterone levels that optimize symptom relief and quality of life. 1

Rationale for Dose Adjustment

The Endocrine Society Clinical Practice Guidelines explicitly state that testosterone therapy should aim to raise serum testosterone levels into the mid-normal range 1. Your patient's level of 174 ng/dL falls significantly short of this target:

• Target range: Mid-normal is approximately 450-600 ng/dL 2
• Current level: 174 ng/dL is in the hypogonadal range (below 300 ng/dL)
• Injectable testosterone threshold: For injectable testosterone enanthate or cypionate specifically, guidelines recommend adjusting dose or frequency if testosterone is <400 ng/dL 1

Your patient is clearly below this threshold and requires dose escalation.

Formulation-Specific Dosing Considerations

The approach to dose adjustment depends on the testosterone formulation being used:

For Injectable Testosterone (Enanthate/Cypionate):

• Measure testosterone level midway between injections 1
• If level is <400 ng/dL (as in your patient), adjust dose or frequency 1
• FDA-approved dosing range: 50-400 mg every 2-4 weeks 3
• Consider increasing dose or shortening injection interval (e.g., from every 2 weeks to weekly) 4

For Transdermal Gels:

• Assess testosterone level anytime after at least 1 week on treatment 1
• Adjust dose to achieve mid-normal range 1
• Typical escalation: increase gel dose by one pump actuation 5, 6

For Transdermal Patches:

• Assess 3-12 hours after patch application 1
• Adjust dose to achieve mid-normal range 1

Timing of Measurement Matters

Critical pitfall: Ensure the testosterone level was measured at the appropriate time for the formulation:

• Injectable testosterone: Should be measured midway between injections, NOT at trough (just before next injection) 1
• If measured at trough, the level will be artificially low and may not reflect average exposure
• If your patient's 174 ng/dL was measured at trough for injectable therapy, the true mid-cycle level might be higher, but likely still subtherapeutic

Monitoring After Dose Increase

After increasing the dose:

1. Recheck testosterone level in 3-6 months to confirm achievement of mid-normal range 1
2. Check hematocrit at 3-6 months (stop therapy if >54%) 1
3. Monitor PSA if patient is ≥40 years old with baseline PSA >0.6 ng/mL 1
4. Assess symptom response (sexual function, energy, mood) 1

Safety Considerations Before Dose Escalation

Before increasing the dose, verify that the patient does not have contraindications to higher testosterone levels:

• Hematocrit <50% at baseline (relative contraindication if ≥50%) 1
• No rapid PSA rise (>1.4 ng/mL in 12 months or velocity >0.4 ng/mL/year) 1
• No abnormal digital rectal exam 1
• No severe sleep apnea (evaluate if hematocrit rises) 1

Why Mid-Normal Range Matters

Achieving mid-normal testosterone levels (not just "normal") is associated with:

• Improved sexual function (libido and erectile function) 1, 7, 2
• Better body composition (increased lean mass, reduced fat mass) 7, 2
• Enhanced bone mineral density 7, 2
• Improved quality of life and mood 5, 6, 7

Subtherapeutic levels like 174 ng/dL will not provide adequate symptom relief or the metabolic benefits of testosterone replacement therapy.

Practical Dose Adjustment Algorithm

1. Confirm formulation and timing of the 174 ng/dL measurement
2. If injectable testosterone: Increase dose by 25-50% OR shorten injection interval (e.g., every 2 weeks → weekly)
3. If transdermal gel: Increase by one pump actuation (typically 23-25 mg testosterone)
4. Recheck testosterone in 3-6 months at appropriate timing for formulation
5. Continue titrating until mid-normal range achieved (450-600 ng/dL)

The goal is not simply to normalize testosterone but to optimize it within the mid-normal physiologic range to maximize clinical benefit and quality of life. 1, 2